Trial Profile
Phase IV clinical trial of TO-194SL -Evaluation of long-term efficacy and safety in patients with Japanese cedar pollinosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Japanese cedar pollen allergy immunotherapy Torii Pharmaceutical (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors Torii Pharmaceutical
- 11 Nov 2014 New trial record